Pharma MarXMAD:PHM +1.11%86 PB Ratio is 5.05 as of Jun. 26, 2026, which is 39% below its 10-year median of 8.24. GuruFocus rates XMAD:PHM with a GF Score™ of 86/100 and a GF Value™ of €83.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Pharma Mar ranks worse than 72% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Pharma Mar's share price is €72.90. Pharma Mar's Book Value per Share for the quarter that ended in Mar. 2026 was €14.43. Hence, Pharma Mar's PB Ratio of today is 5.05.
Good Sign:
Pharma Mar SA stock PB Ratio (=4.82) is close to 1-year low of 4.64.
The historical rank and industry rank for Pharma Mar's PB Ratio or its related term are showing as below:
XMAD:PHM'
s PB Ratio Range Over the Past 10 Years
Min: 2.38 Med: 8.24 Max: 3510.87
Current: 5.06
During the past 13 years, Pharma Mar's highest PB Ratio was 3510.87. The lowest was 2.38. And the median was 8.24.
XMAD:PHM's PB Ratio is ranked worse than 72% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs XMAD:PHM: 5.06
During the past 12 months, Pharma Mar's average Book Value Per Share Growth Rate was 27.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharma Mar was 171.50% per year. The lowest was -40.00% per year. And the median was -0.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pharma Mar PB Ratio Related Terms
Pharma Mar PB Ratio Historical Data
* Premium members only.
The historical data trend for Pharma Mar's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharma Mar's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pharma Mar's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Pharma Mar's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pharma Mar (XMAD:PHM) has a PB Ratio of 5.05 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharma Mar and its competitors. This is 39% below median its historical median of 8.24. Over the past decade, Pharma Mar's PB Ratio has ranged from 2.38 to 3,510.87. According to the industry distribution chart, Pharma Mar ranks #887 out of 1232 companies in the Biotechnology industry, placing it in the top 72%.
Is Pharma Mar's PB Ratio too high?
Pharma Mar's current PB Ratio of 5.05 is 39% below median its 10-year median of 8.24. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 3,510.87. The Biotechnology industry median PB Ratio is 2.80. Pharma Mar's value of 5.05 is 80.4% above this industry median. Based on the distribution chart, Pharma Mar ranks #887 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharma Mar has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #887 out of 1232 companies for PB Ratio. This places Pharma Mar in the lower half of its industry. The industry median PB Ratio is 2.80. Pharma Mar's value of 5.05 is 80.4% above this benchmark. Historically, Pharma Mar's own PB Ratio has ranged from 2.38 to 3,510.87 over the past decade. While the company's 10-year median is 8.24 vs. the industry median of 2.80, Pharma Mar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Mar's current PB Ratio of 5.05 is 80.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharma Mar and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Mar's current PB Ratio is 5.05, which is 39% below median its own 10-year median of 8.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (XMAD:PHM) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.14, compared to a current price of €72.90 — trading 12.3% below its estimated fair value. The current PB Ratio is 5.05, which is 39% below median its 10-year median of 8.24 and 80.4% above the Biotechnology industry median of 2.80. Pharma Mar's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pharma Mar (XMAD:PHM), the current PB Ratio is 5.05 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (XMAD:PHM) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €72.90 is trading 12.3% below its estimated GF Value™ of €83.14.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for XMAD:PHM:
PB Ratio: 5.05 (39% below median its 10-year median of 8.24)
GF Value™: €83.14 vs. price of €72.90 (12.3% below fair value)
Industry Position: 80.4% above the Biotechnology median (#887 of 1232)
No single metric tells the full story. See the XMAD:PHM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
86GF Score
Get the complete analysis for XMAD:PHM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PHM has been successfully added to your 
